title: LONGITUDINAL MICROPERIMETRY EVALUATION AFTER INTRAVITREAL OCRIPLASMIN INJECTION FOR VITREOMACULAR TRACTION.
abstract: OBJECTIVE
  To determine whether improvements in microperimetry testing are associated with anatomic resolution after ocriplasmin treatment in patients with symptomatic vitreomacular adhesion (VMA)/vitreomacular traction and relatively preserved baseline best-corrected visual acuity (BCVA).
  
  
  METHODS
  Patients with vitreomacular traction received a single 125-μg intravitreal ocriplasmin injection and were followed longitudinally for 6 months with optical coherence tomography, BCVA testing, and microperimetry. Visual function changes were compared between eyes with and without VMA resolution on optical coherence tomography.
  
  
  RESULTS
  Eleven of 16 eyes (68.8%) achieved VMA resolution after treatment. Mean baseline BCVA was relatively good (79 ± 3 Early Treatment Diabetic Retinopathy Study letters; 20/52); no patients had a ≥2-line improvement in BCVA over the 6-month follow-up period. In the group with VMA resolution, mean retinal sensitivity significantly increased in the central 4° (15.2 ± 1.9 dB vs. 18.9 ± 0.7 dB, P < 0.001) when comparing baseline and final follow-up microperimetry testing. No change in mean retinal sensitivity was found in the group without VMA resolution.
  
  
  CONCLUSIONS
  Microperimetry demonstrates a significant gain in retinal sensitivity, particularly in the central 4° area, in eyes with anatomic resolution after treatment of vitreomacular traction with intravitreal ocriplasmin injection, even when no significant gain in BCVA is seen.
authors.affiliation: *G.B. Bietti Eye Foundation-IRCCS, Rome, Italy; †Department of Ophthalmology, Clinica Villa dei Fiori, Acerra, Naples, Italy; ‡Department of Ophthalmology, Feinberg School of Medicine, Northwestern University, Chicago, Illinois; and §Department of Ophthalmology, San Giovanni-Addolorata Hospital, Rome, Italy.
authors.forename: Andrea
authors.initials: A
authors.lastname: Cacciamani
authors.forename: Aldo
authors.initials: A
authors.lastname: Gelso
authors.forename: Joseph M
authors.initials: JM
authors.lastname: Simonett
authors.forename: Guido
authors.initials: G
authors.lastname: Ripandelli
authors.forename: Marco
authors.initials: M
authors.lastname: Pileri
authors.forename: Mario
authors.initials: M
authors.lastname: Stirpe
authors.forename: Fabio
authors.initials: F
authors.lastname: Scarinci
mesh_terms: D000368:Aged; D015331:Cohort Studies; D005260:Female; D005341:Fibrinolysin / Q000008:administration & dosage*; D006801:Humans; D058449:Intravitreal Injections; D008137:Longitudinal Studies; D008297:Male; D008875:Middle Aged; D010446:Peptide Fragments / Q000008:administration & dosage*; D012164:Retinal Diseases / Q000175:diagnosis* / Q000188:drug therapy / Q000503:physiopathology; D041623:Tomography, Optical Coherence; D016896:Treatment Outcome; D014792:Visual Acuity; D058609:Visual Field Tests / Q000379:methods*; D014794:Visual Fields / Q000502:physiology*; D020255:Vitreous Detachment / Q000175:diagnosis* / Q000188:drug therapy / Q000503:physiopathology
chemical_list: D010446:Peptide Fragments; C054561:microplasmin; D005341:Fibrinolysin